Related Experiment Video
Updated: Jan 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Juan Gómez Rivas1,2, Diego M Carrion3,4, Mario Alvarez-Maestro3,4
1Department of Urology, La Paz University Hospital, Madrid, Spain - juangomezr@gmail.com.
Bone-targeted agents (BTAs) improve outcomes in metastatic castration-resistant prostate cancer (mCRPC) when combined with life-prolonging therapies. Further research will refine optimal BTA strategies and explore novel agents like PSMA-targeted therapies for mCRPC management.
Area of Science:
- Oncology
- Pharmacology
- Radiopharmaceuticals
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) treatment has advanced significantly.
- Bone-targeted agents (BTAs) combined with life-prolonging therapies improve clinical benefit.
- This review assesses BTAs in the evolving landscape of mCRPC management.
Purpose of the Study:
- Provide an overview of BTA data in mCRPC.
- Critically assess the use of BTAs in mCRPC.
- Evaluate novel targeted therapies for mCRPC.
Main Methods:
- Non-systematic literature review.
- Keywords: "castration-resistant prostate cancer" and "bone-targeted therapy".
Main Results:
- Zoledronic acid and denosumab reduce skeletal-related events (SREs) in mCRPC.
- Optimal timing for bisphosphonate/denosumab initiation requires further determination.
- Radium-223 (Ra-223) use is restricted; PSMA-targeted radioligand therapy (RLT) agents are under investigation.
Conclusions:
- Reducing skeletal morbidity is key in mCRPC palliative care.
- Optimizing BTA integration requires further data on dosing and combinations.
- Novel PSMA-targeted agents offer potential theranostic applications for prostate cancer (PCa).
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Standing Waves
Standing Electromagnetic Waves
Suppose a sheet of a perfect conductor is placed in the yz-plane, and a linearly polarized electromagnetic wave traveling in the...
Standing Waves in a Cavity

